Table 1. Abl mutant MARCM clones.
| (A) Ablmut/ Ablmut MARCM clones. | |||||
| Neuroblast clones | |||||
| Genotype | WT | Absence of α lobe | Absence of β lobe | Absence of α/β lobes | n |
| Control |
22 100% |
-- | -- | -- | 22 |
| Abl2 / Abl2 |
43 90% |
5 10% |
-- | -- | 48 |
| Abl4 / Abl4 |
37 82% |
5 11% |
3 7% |
-- | 45 |
| Abl1 / Abl1 |
71 92% |
3 4% |
3 4% |
-- | 77 |
| (B) Visualization Abl2/Abl4 MARCM clones. | |||||
| Two-cells / Single-cell clones | |||||
| Genotype | WT | α branch growth defect | β branch growth defect | α/β branch growth defects | n |
| Control |
30 100% |
-- | -- | -- | 30 |
| Abl2 / Abl4 |
2 13% |
10 67% |
-- |
3 20% |
15 |
| >Two-cells clones | |||||
| Genotype | WT | Absence of α lobe | Absence of β lobe | Absence of α/β lobes | n |
| Control |
9 100% |
-- | -- | -- | 9 |
| Abl2 / Abl4 |
6 23% |
14 54% |
2 8% |
4 15% |
26 |
| Neuroblast clones | |||||
| Genotype | WT | Absence ofα lobe | Absence of β lobe | Absence of α/β lobes | n |
| Control |
9 100% |
-- | -- | -- | 9 |
| Abl2 / Abl4 |
2 17% |
7 58% |
-- |
3 25% |
12 |
WT: wild-type clones. n: number of clones analyzed.
Full genotypes: A) Control: y w67c23 hs-FLP122 / +; c739-GAL4 UAS-mCD8-GFP / +; tubP-GAL80, FRT2A / FRT2A. Mutant:. y w67c23 hs-FLP122 / +; c739-GAL4 UAS-mCD8-GFP / +; tubP-GAL80, FRT2A / Abl2 FRT2A. y w67c23 hs-FLP122 / +; c739-GAL4 UAS-mCD8-GFP / +; tubP-GAL80, FRT2A / Abl4 FRT2A. y w67c23 hs-FLP122 / +; c739-GAL4 UAS-mCD8-GFP / +; tubP-GAL80, FRT2A / Abl1 FRT2A. B) Control: w* tubP-GAL80 hs-FLP122 FRT19A / w* sn FRT19A; c739-GAL4 UAS-mCD8-GFP / UAS-mCD8-GFP. Abl2/Abl4: w* tubP-GAL80 hs-FLP122 FRT19A / w* sn FRT19A; c739-GAL4 UAS-mCD8-GFP / UAS-mCD8-GFP; Abl2 / Abl4.